TIAN YUAN HEALTHCARE
天 元 医 疗

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED
中國天元醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 557)

(1) NOTIFICATION OF BOARD MEETING;
(2) UPDATE ON THE DESPATCH OF THE 2020 INTERIM REPORT AND THE 2020 ANNUAL REPORT; AND
(3) CONTINUED SUSPENSION OF TRADING

This announcement is made by the board of directors (the "**Board**") of China Tian Yuan Healthcare Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated (i) 30 September 2020 in relation to the delay in publication of the 2020 Interim Results and the despatch of the 2020 Interim Report; (ii) 15 December 2020 in relation to the further delay in publication of the 2020 Interim Results and despatch of the 2020 Interim Report; (iii) 31 March 2021 in relation to (a) the further delay in publication of the 2020 Interim Results and despatch of the 2020 Interim Report and (b) the delay in publication of the 2020 Annual Results and despatch of the 2020 Annual Report; (iv) 9 April 2021 in relation to the notification of board meeting; (v) 21 April 2021 in relation to the change of date of board meeting; (vi) 22 April 2021 in relation to the clarification announcement to the change of date of board meeting; and (vii) 26 April 2021 in relation to the further delay in publication of the 2020 Interim Results and the 2020 Annual Results (together, the "**Announcements**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined in the Announcements.

(1) NOTIFICATION OF BOARD MEETING

The Board announces that a meeting of the Board of the Company will be held on Friday, 21 May 2021 at 4 p.m. for the purpose of, inter alia, considering and approving the unaudited interim results of the Group for the six months ended 30 June 2020, the audited annual results of the Group for the year ended 31 December 2020 and their publication and considering the payment of an interim and a final dividend (if any).

(2) UPDATE ON THE DESPATCH OF THE 2020 INTERIM REPORT AND THE 2020 ANNUAL REPORT

Pursuant to Rule 13.48(1) and Rule 13.46(2)(a) of the Listing Rules, the Company is required to despatch the interim report for the six months ended 30 June 2020 (the "**2020 Interim Report**") to the shareholders of the Company on or before 30 September 2020 and the annual report of the Company for the year ended 31 December 2020 (the "**2020 Annual Report**") to the shareholders of the Company on or before 30 April 2021.

The publication of the 2020 Interim Results and 2020 Annual Results will be scheduled on 21 May 2021. Due to the delay in the preparation and publication of the 2020 Interim Results and 2020 Annual Results, it is expected that the 2020 Interim Report and the 2020 Annual Report will be despatched to the shareholders of the Company on or before 4 June 2021.

(3) CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended with effect from 9:00 a.m. on Monday, 24 August 2020 and will remain suspended until further notice.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Tian Yuan Healthcare Group Limited
Zhang Xian
Executive Director

Hong Kong, 11 May 2021

As at the date of this announcement, the Board is comprised of seven directors of which Mr. Wang Huabing (Chairman) and Ms. Zhang Xian are the executive directors; Ms. He Mei and Mr. Zhou Yuan are the non-executive directors; and Mr. Hu Baihe, Mr. Yuen Kwok Kuen and Mr. Guo Jingbin are the independent non-executive directors.